Value of PCT When Diagnosing Candidemia

May 19, 2022 updated by: Johan Petersson, Karolinska University Hospital
This study is a retrospective analysis to identify and compare the shift in inflammatory biomarkers in ICU patients immediately before and after the first identification of candidemia.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

As above.

Study Type

Observational

Enrollment (Actual)

49

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Sweden
      • Stockholm, Sweden, 17176
        • Karolinska University Hospital Solna

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Intensive care patients

Description

Inclusion Criteria (all has to be fullfilled):

  • ICU patients with blood cultures showing growth of Candida species
  • clinical records including daily data on WBC, CRP, Procalcitonin and body temperature

Exclusion Criteria:

  • Age lower than 18 years
  • blood cultures with growth of Candida species before ICU admission
  • incomplete records of daily WBC, CRP, Procalcitonin or body temperature

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Absolute procalcitonin concentration
Time Frame: 9 days
9 days
Shift (trend) procalcitonin concentration
Time Frame: 9 days
9 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Karolinska University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 1, 2010

Primary Completion (ACTUAL)

December 31, 2015

Study Completion (ACTUAL)

December 12, 2021

Study Registration Dates

First Submitted

December 12, 2021

First Submitted That Met QC Criteria

May 19, 2022

First Posted (ACTUAL)

May 23, 2022

Study Record Updates

Last Update Posted (ACTUAL)

May 23, 2022

Last Update Submitted That Met QC Criteria

May 19, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EPN 2017/806-31 (Candida-PCT)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

No plan

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on The Value of Procalcitonin in Patients With Suspected Candidemia

Clinical Trials on Serum procalcitonin concentration

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe